| Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases D Rufino-Ramos, PR Albuquerque, V Carmona, R Perfeito, RJ Nobre, ... Journal of Controlled Release 262, 247-258, 2017 | 363 | 2017 |
| Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway J Cunha-Santos, J Duarte-Neves, V Carmona, L Guarente, ... Nature communications 7 (1), 11445, 2016 | 106 | 2016 |
| miRNA-31 improves cognition and abolishes amyloid-β pathology by targeting APP and BACE1 in an animal model of Alzheimer’s disease AT Barros-Viegas, V Carmona, E Ferreiro, J Guedes, AM Cardoso, ... Molecular Therapy-Nucleic Acids 19, 1219-1236, 2020 | 69 | 2020 |
| Unravelling endogenous microRNA system dysfunction as a new pathophysiological mechanism in Machado-Joseph disease V Carmona, J Cunha-Santos, I Onofre, AT Simões, U Vijayakumar, ... Molecular Therapy 25 (4), 1038-1055, 2017 | 52 | 2017 |
| Control of Huntington’s disease-associated phenotypes by the striatum-enriched transcription factor Foxp2 LJ Hachigian, V Carmona, RJ Fenster, R Kulicke, A Heilbut, A Sittler, ... Cell reports 21 (10), 2688-2695, 2017 | 28 | 2017 |
| Gene therapies for polyglutamine diseases CA Matos, V Carmona, UG Vijayakumar, S Lopes, P Albuquerque, ... Polyglutamine Disorders, 395-438, 2018 | 24 | 2018 |
| Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3 D Rufino-Ramos, PR Albuquerque, K Leandro, V Carmona, IM Martins, ... Molecular Therapy 31 (5), 1275-1292, 2023 | 9 | 2023 |
| SIRT2 deficiency exacerbates hepatic steatosis via a putative role of the ER stress pathway H Leal, J Cardoso, P Valério, M Quatorze, V Carmona, J Cunha-Santos, ... International Journal of Molecular Sciences 23 (12), 6790, 2022 | 9 | 2022 |
| Identification of the calpain‐generated toxic fragment of ataxin‐3 protein provides new avenues for therapy of Machado–Joseph disease| Spinocerebellar ataxia type 3 AT Simões, V Carmona, J Duarte‐Neves, J Cunha‐Santos, ... Neuropathology and Applied Neurobiology 48 (1), e12748, 2022 | 6 | 2022 |
| Nuclear aging in polyglutamine-induced neurodegeneration D Pereira, J Cunha-Santos, A Vasconcelos-Ferreira, J Duarte-Neves, ... bioRxiv, 2023.06. 09.544056, 2023 | | 2023 |
| Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease (MJD)/Spinocerebellar Ataxia type-3 (SCA3) D Rufino-Ramos, K Leandro, P Albuquerque, V Carmona, I Martins, ... HUMAN GENE THERAPY 33 (23-24), A178-A178, 2022 | | 2022 |
| Extracellular vesicles for therapy of spinocerebellar ataxia type 3 D Rufino-Ramos, V Carmona, IM Martins, M Barreira, PR Albuquerque, ... HUMAN GENE THERAPY 30 (11), A101-A101, 2019 | | 2019 |
| MicroRNAs targeting Ataxin-3 mRNA in Machado-Joseph disease: from pathogenesis to therapy VMM Carmona Universidade de Coimbra, 2017 | | 2017 |
| MicroRNAs modulation: a new therapeutic approach for Alzheimer’s disease A Viegas, V Carmona, J Guedes, AR Oliveira, LP de Almeida, ... European Neuropsychopharmacology 2 (26), S635-S636, 2016 | | 2016 |
| Dissecting the role of microRNAs and their therapeutic potential in Alzheimer's disease AT Viegas, V Carmona, L Pereira de Almeida, JP de Magalhaes, ... FEBS JOURNAL 282, 217-217, 2015 | | 2015 |
| 582. Role of MicroRNA Deregulation in Machado-Joseph Disease UG Vijayakumar, V Carmona, C Nóbrega, L Ferreira, LP de Almeida Molecular Therapy 23, S231-S232, 2015 | | 2015 |
